🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Mucosal Associated Invariant T Cell During Viral Pneumonia and Acute Respiratory Distress Syndrome

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Tours
NCT06720818 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Viral pneumonia, including SARS-CoV-2 and influenza A virus (IAV), can culminate in acute respiratory distress syndrome (ARDS), a severe form of respiratory failure with high mortality. Uncontrolled local inflammatory response and impaired tissue repair are hallmarks of ARDS. However, lack of in-depth understanding of the immunopathology lead to limited identification of potential 'endotypes' who may benefit from individualized targeted therapies. Mucosal Associated Invariant T (MAIT) cells represent a peculiar lineage of T cells with a wide panel of effector functions. Thus, they emerge as potential key players and appealing targets in ARDS through their potent abilities to modulate immune response at barrier sites and promote tissue repair. Recent data from the investigators and others indicated that MAIT cells are highly activated in patients with Sars-Cov-2 and IAV ARDS, but the asso

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Patients admitted to critical care (Intensive Care Unit, Continuous Monitoring Unit, Intensive Care Unit) at the CHRU de Tours * Patients admitted to critical care for one of the following reasons: * Acute community-acquired pulmonary infection (pneumonia), * Severe acute pancreatitis, with onset of ARDS criteria less than 48 hours ago, * Severe isolated head injury requiring invasive mechanical ventilation, * Severe burn defined by a burned surface area exceeding 20% and/or deep lesions exceeding 3% of the total body surface area, with the onset of ARDS criteria less than 48 hours ago, * Patient admitted to Intensive Care Medicine, requiring invasive mechanical ventilation, * Patient admitted to cardiac surgery for scheduled surgery for valve replacement and/or coronary artery bypass grafting, with inclusion the day before surgery, Non-inclusion criteria : * Patients with severe immunosuppression (impairing the ability to analyse the immune response, particularly T lymphocytes): active haematological malignancy, solid organ transplantation or bone marrow transplantation, systemic immunosuppressive treatment, ongoing chemotherapy (including immune checkpoint inhibitors). * Person who has objected to data processing * Patient under guardianship or curatorship
💊

What it tests

  • Not listed
📍

Where

1 site
University hospital
Tours, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy